{'fraction_non_alphanumeric': 0.020924149956408022, 'fraction_numerical': 0.0034873583260680036, 'mean_word_length': 6.358974358974359, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Bevacizumab for acute neurologic deterioration in patients with glioblastoma.

AIM
Glioblastoma causes neurologic dysfunction owing to the tumor's location and peritumoral edema. Bevacizumab improves symptoms and steroid dependence, and may rescue glioblastoma patients hospitalized for acute neurologic dysfunction, allowing them to return home for outpatient treatment.


MATERIALS & METHODS
We carried out a retrospective review of glioblastoma patients with severe neurologic dysfunction who received bevacizumab as inpatients.


RESULTS
Nine patients (median age: 51 years; median Karnofsky Performance Status [KPS]: 40%) received one dose of bevacizumab while admitted for neurologic deterioration. Seven patients were treated at recurrence, two at diagnosis. Six patients clinically improved and continued outpatient treatment, while five decreased/discontinued dexamethasone.


CONCLUSION
Single bevacizumab treatment administered to naive hospitalized patients with glioblastoma improves function and quality of life through avoidance of prolonged hospitalization and rehabilitation admissions, and decreased dexamethasone administration.